Aberdeen Wealth Management LLC Has $210,000 Holdings in Merck & Co., Inc. (NYSE:MRK)

Aberdeen Wealth Management LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 55.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,853 shares of the company’s stock after selling 2,265 shares during the period. Aberdeen Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $210,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Merck & Co., Inc. by 10.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 55,281 shares of the company’s stock worth $7,332,000 after buying an additional 5,088 shares in the last quarter. Quent Capital LLC lifted its holdings in shares of Merck & Co., Inc. by 11.4% in the first quarter. Quent Capital LLC now owns 10,236 shares of the company’s stock worth $1,351,000 after acquiring an additional 1,048 shares during the last quarter. InterOcean Capital Group LLC lifted its holdings in shares of Merck & Co., Inc. by 16.2% in the first quarter. InterOcean Capital Group LLC now owns 16,275 shares of the company’s stock worth $2,147,000 after acquiring an additional 2,264 shares during the last quarter. Evermay Wealth Management LLC boosted its stake in shares of Merck & Co., Inc. by 5.8% in the 1st quarter. Evermay Wealth Management LLC now owns 18,379 shares of the company’s stock valued at $2,436,000 after purchasing an additional 1,013 shares in the last quarter. Finally, Elgethun Capital Management grew its holdings in shares of Merck & Co., Inc. by 74.8% during the 1st quarter. Elgethun Capital Management now owns 12,210 shares of the company’s stock valued at $1,592,000 after purchasing an additional 5,224 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $96.56 on Tuesday. The company has a market capitalization of $244.26 billion, a PE ratio of 20.24, a P/E/G ratio of 1.38 and a beta of 0.40. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. Merck & Co., Inc. has a twelve month low of $94.48 and a twelve month high of $134.63. The firm has a fifty day simple moving average of $108.46 and a 200 day simple moving average of $118.60.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. The firm had revenue of $16.66 billion during the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the company posted $2.13 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 7.75 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MRK. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research report on Thursday, October 3rd. Guggenheim cut their price objective on Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. UBS Group lowered their target price on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Wolfe Research assumed coverage on Merck & Co., Inc. in a research report on Friday. They issued a “peer perform” rating for the company. Finally, Citigroup reduced their price target on Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $130.86.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.